Page 5 - Clinj Am Soc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Using DOACs in People with Chronic Kidney Disease, with Kim Zuber, PA-C, and Jane Davis, DNP

Kim Zuber, PA-C, and Jane Davis, DNP, offer insight into the use of DOACs in people with atrial fibrillation and chronic kidney disease.

Kim zuberJane davisConference steering committeeEnd stage kidney diseaseKidney disease improving global outcomesConference steeringKidney diseaseImproving global outcomesAtrial fibrillationChronic kidneyClinj am socAcute kidney injuryOral anticoagulantsElderly adultsVenous thromboembolismPatients receiving long term

Have Racial Disparities in Home Dialysis Utilization Changed Over Time?

Medicare prospective payment for dialysis modestly increased availability and use of home-based dialysis treatment but did not affect historic racial disparities in home dialysis.

District of columbiaUnited statesDivision of nephrologyResearch career scientistOxford universityOffice of researchHealth drugArea health resources filesMedicare provider of serviceDepartment of medicineHealth serv resDepartment of biostatisticsDuke university school of medicineDurham veterans affairs health care systemHealth services researchDevelopment service

Clinical Overview: Innovations in Nephrology 2023

It is important for pharmacists to understand implications related to drug clearance to maximize therapeutics in patients with kidney disease.

United statesRoxanna seyedinIndianj nephrolLas vegasClin pharmacolKrithika rajagopalanInnovation fund in relavoRelavo incNational healthcare safety networkAmerican society of nephrology kidney weekCormedix incJames dyson foundationNational institute of diabetesNational kidney foundationNational institutes of healthKidney international

Discoveries & Impact (February 2023)

Discoveries & Impact highlights select scientific discoveries across the Department of Internal Medicine.

United statesSouth koreaSri lankaKimg smolderenMario strazzaboscoYale hepatologistsCarlos mena hurtadoMultimorbidity comorbidityAriel jaffeJohns hopkinsMultimorb comorbDepartment of internal medicineYale diabetes centerInterest group of the american thoracic societySociety of vascular surgerySectional north american

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesChristine regan lindenboomJorge capapeyJosh brodskyKim hollanderHyperoxaluria foundationGlobal rare disease lead at alnylam pharmaceuticalsDrug administrationAlnylam pharmaceuticals incExchange commissionAlnylam pharmaceuticalsEuropean medicines agencyCommittee for medicinal products human usePrimary hyperoxaluria typeLower urinary